Date: 2017-09-07
Type of information: Research agreement
Compound: tumor-infiltrating lymphocyte (TIL), marrow-infiltrating lymphocyte (MIL) and peripheral blood-associated lymphocyte technologies
Company: Iovance Biotherapeutics (US - CA) The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) (USA - OH)
Therapeutic area: Cancer - Oncology
Type agreement: research - R&D
Action mechanism:
- immunotherapy product/cell therapy
Disease: hematologic malignancies including acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
Details:
- • On September 7, 2017, Iovance Biotherapeutics announced that it has entered into a preclinical research collaboration with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) focused on TIL, marrow-infiltrating lymphocyte (MIL) and peripheral blood-associated lymphocyte technologies.
- The collaboration will initially focus on hematologic malignancies in areas of poor prognostic cancers with high unmet medical need, which include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). The collaboration will be co-led by Iovance researchers and by Dr. John Byrd, D. Warren Brown Chair of Leukemia Research, Distinguished University Professor of Medicine, Medicinal Chemistry and Veterinary Biosciences at the OSUCCC – James.
Financial terms:
Latest news:
Is general: Yes
